ANTON M MELNYK

Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology ABILENE, TX NPI 1801834544

General Payments — all program years on this page

$18,116.67

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 92
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $4,756.06 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $2,850.001
Food and Beverage $1,366.2517
Travel and Lodging $539.812

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2018 $5,861.6729
2019 $857.5215
2020 $1,383.032
2021 $1,361.922
2022 $2,601.8510
2023 $1,294.6214
2024 $4,756.0620

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1078859020 Janssen Scientific Affairs, LLC $102.17 10/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1089456110 Daiichi Sankyo Inc. $104.75 12/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101347860 E.R. Squibb & Sons, L.L.C. $86.84 05/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105305218 AstraZeneca Pharmaceuticals LP $72.22 06/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116623775 GlaxoSmithKline, LLC. $79.87 10/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117326327 Amgen Inc. $113.63 03/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1120860149 BeiGene USA, Inc. $14.62 10/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1126824439 Genmab U.S., Inc. $95.26 04/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133599429 Gilead Sciences, Inc. $2,850.00 10/17/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1133803566 Gilead Sciences, Inc. $115.38 10/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133803568 Gilead Sciences, Inc. $56.65 10/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133803570 Gilead Sciences, Inc. $56.65 10/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133803572 Gilead Sciences, Inc. $59.96 10/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133866548 Gilead Sciences, Inc. $303.97 10/11/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1133866550 Gilead Sciences, Inc. $235.84 10/23/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1136048953 Lilly USA, LLC $99.05 01/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139621369 GENZYME CORPORATION $112.20 11/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141843141 Merck Sharp & Dohme LLC $97.20 02/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1145527964 Karyopharm Therapeutics Inc. $21.25 12/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1149320276 Dendreon Pharmaceuticals LLC $78.55 11/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.